Abstract
Worldwide, at least a quarter of the patients with colorectal cancer (CRC) are diagnosed with metastatic disease at presentation and many of them eventually succumb to their disease. A third of these patients may have their metastatic disease burden confined to the liver. It has been estimated that about 15–25% of CRC patients initially present with synchronous resectable liver metastases (SRLM) (1). These patients represent a group whose oncologic prognosis has significantly improved over the past decades (2).
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call